ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

The Comparative Safety and Efficacy of Direct Acting Oral Anticoagulants Relative to Warfarin Following Liver Transplantation

A. Santeusanio, A. Weinberg, T. Schiano

Mount Sinai Hospital, New York, NY

Meeting: 2019 American Transplant Congress

Abstract number: 231

Keywords: Anticoagulation, Blood transfusion, Liver transplantation, Pharmacokinetics

Session Information

Date: Monday, June 3, 2019

Session Name: Concurrent Session: Liver Transplant Complications and Retransplantation I

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:42pm-3:54pm

Location: Ballroom A

Related Abstracts
  • Direct Oral Anticoagulation Use in Kidney Transplant Recipients
  • Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Solid Organ Transplant Recipients

*Purpose: This study describes the comparative safety and efficacy of direct acting oral anticoagulants (DOACs) relative to warfarin following liver transplantation, at a large academic transplant center.

*Methods: This was a single-center, retrospective cohort review of adult liver transplant recipients prescribed either a DOAC or warfarin between January 2014 and January 2018. Patients were excluded if they had active cancer or discontinued anticoagulation therapy prior to 60 days for a reason other than acute bleeding or thrombosis. Patients receiving DOACs were matched with warfarin treated controls using an exact greedy matching algorithm based upon the following clinical parameters: donor type, age, history of hepatocellular carcinoma, indication for anticoagulation, HAS-BLED score, timing of anticoagulation, and duration of anticoagulation. Matched patients were then followed from the time of anticoagulation initiation, until treatment discontinuation or study conclusion. The primary endpoint for this review was the incidence of clinically significant bleeding between the two treatment groups. Secondary endpoints included incidence of major bleeding, incidence of new thrombotic complications, and change in calcineurin inhibitor trough/dose ratios at 30-days post-DOAC initiation.

*Results: A total of 27 patients prescribed DOACs were identified for inclusion in the study. Among these patients, there were 4 episodes of clinically significant bleeding and 4 instances of new or recurrent thrombosis over a median of 351 (61-784) anticoagulation days. Exact warfarin matches could be found for 20 out of the 27 patients originally managed with DOACs. Demographic and clinical characteristics were similar between the two treatment groups at baseline. At the conclusion of the study review period, the DOAC treated patients were found to have significantly lower rates of clinically significant bleeding (3 events vs. 10 events; p = 0.01) and major bleeding (0 events vs. 4 events). No statistically significant differences were found in the rates of new or recurrent thrombotic events between the DOAC and warfarin arms (4 events vs. 3 events; p = 0.67), and no differences were observed in tacrolimus trough/dose ratios at 30-days following DOAC initiation. After logistic regression, treatment assignment with warfarin continued to be associated with a significantly higher odds of clinically significant bleeding (OR = 12.1; CI 1.4-106.3).

*Conclusions: In our patient cohort, DOAC use resulted in similar efficacy relative to warfarin in preventing new or recurrent thrombosis, but was associated with less clinically significant bleeding. A variety of clinical and patient specific risk factors still bear consideration when selecting between the various anticoagulant options.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Santeusanio A, Weinberg A, Schiano T. The Comparative Safety and Efficacy of Direct Acting Oral Anticoagulants Relative to Warfarin Following Liver Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/the-comparative-safety-and-efficacy-of-direct-acting-oral-anticoagulants-relative-to-warfarin-following-liver-transplantation/. Accessed April 16, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.